Hovione Announces New Director
Hovione recently announced the appointment of Dr. Conrad Winters as Director, Drug Product Development. Dr. Winters was previously with Merck in US and
“We are very pleased to welcome Dr. Winters to Hovione. His experience in particle engineering, solubilization, drug product development, scale-up, and commercialization will enable us to solve our customers’ most challenging problems,” said Dr. Thomas Eisele, Vice President Corporate Research & Development.
“I am delighted to join the strong team at Hovione. Already the recognized world leader in pharmaceutical spray drying, I am looking forward to leading the team in developing complementary technologies to enable Hovione to offer customers’ integrated solutions for any molecule,” added Dr. Winters.
Dr. Winters is a Senior Director with 18 years experience in the pharmaceutical industry with a focus on managing the development of compounds from lead candidate optimization through to NDA submission and commercialization. He has much experience in rational formulation design, based on fundamental understanding of material properties and the adaptation of particle properties to effect improved bioperformance. Dr. Winters has led cross functional global teams charged with the development of priority new chemical entities. He has contributed to and prepared documentation in support of many successful regulatory submissions.
Dr. Winters is a member of the American Association of Pharmaceutical Scientists and of the Royal Pharmaceutical Society of Great Britain. He is author of four patents, ten papers, and is a frequent speaker at international conferences. He trained as a pharmacist at the
Hovione is a global company with over 50 years’ experience in Active Pharmaceutical Ingredient and Drug Product Intermediate development and compliant manufacture. For more information, visit www.hovione.com.
Total Page Views: 964
